Samarth Kulkarni Sells 30,000 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 30,000 shares of the stock in a transaction on Monday, November 11th. The shares were sold at an average price of $55.62, for a total value of $1,668,600.00. Following the completion of the transaction, the chief executive officer now directly owns 196,540 shares in the company, valued at approximately $10,931,554.80. This trade represents a 13.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Samarth Kulkarni also recently made the following trade(s):

• On Monday, October 14th, Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $46.28, for a total value of $198,680.04.

CRISPR Therapeutics Trading Down 5.9 %

CRSP stock opened at $46.85 on Friday. The stock has a 50-day moving average price of $47.80 and a two-hundred day moving average price of $52.12. The stock has a market cap of $4.00 billion, a PE ratio of -16.55 and a beta of 1.67. CRISPR Therapeutics AG has a 1 year low of $43.42 and a 1 year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. The firm had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same quarter in the prior year, the company earned ($1.41) EPS. On average, analysts forecast that CRISPR Therapeutics AG will post -5.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Barclays cut their price target on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 6th. Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a research note on Thursday, August 8th. Stifel Nicolaus cut their price target on CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a research note on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Finally, StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research report on Thursday, November 7th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $74.94.

Hedge Funds Weigh In On CRISPR Therapeutics

Several hedge funds have recently modified their holdings of CRSP. Capital International Investors grew its holdings in shares of CRISPR Therapeutics by 27.8% in the 1st quarter. Capital International Investors now owns 7,837,074 shares of the company’s stock valued at $534,175,000 after acquiring an additional 1,702,624 shares in the last quarter. SR One Capital Management LP bought a new position in shares of CRISPR Therapeutics in the 1st quarter valued at about $71,496,000. Farallon Capital Management LLC bought a new position in shares of CRISPR Therapeutics in the 2nd quarter valued at about $28,625,000. Avoro Capital Advisors LLC bought a new position in shares of CRISPR Therapeutics in the 1st quarter valued at about $28,599,000. Finally, Marshall Wace LLP bought a new position in shares of CRISPR Therapeutics in the 2nd quarter valued at about $10,078,000. Institutional investors own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.